Peripheral tissular analysis of rapamycin’s effect as a neuroprotective agent in vivo
- 27 July 2022
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 395 (10) , 1239-1255
Abstract
Rapamycin is the best-characterized autophagy inducer, which is related to its antiaging and neuroprotective effects. Although rapamycin is an FDA-approved drug for human use in organ transplantation and cancer therapy, its administration as an antiaging and neuroprotective agent is still controversial because of its immunosuppressive and reported side effects. Therefore, it is critical to determine whether the dose that exerts a neuroprotective effect, 35 times lower than that used as an immunosuppressant agent, harms peripheral organs. We validated the rapamycin neuroprotective dosage in a Parkinsonʼs disease (PD) model induced with paraquat. C57BL/6 J mice were treated with intraperitoneal (IP) rapamycin (1 mg/kg) three times per week, followed by paraquat (10 mg/kg) twice per week for 6 weeks, along with rapamycin on alternate days. Rapamycin significantly decreased dopaminergic neuronal loss induced by paraquat. Since rapamycin’s neuroprotective effect in a PD model was observed at 7 weeks of treatment; we evaluated its effect on the liver, kidney, pancreas, and spleen. In addition, we prolonged treatment with rapamycin for 14 weeks. Tissue sections were subjected to histochemical, immunodetection, and morphometric analysis. Chronic rapamycin administration does not affect bodyweight, survival, and liver or kidney morphology. Although the pancreas tissular architecture and cellular distribution in Langerhans islets are modified, they may be reversible. The spleen B lymphocyte and macrophage populations were decreased. Notably, the lymphocyte T population was not affected. Therefore, chronic administration of a rapamycin neuroprotective dose does not produce significant tissular alterations. Our findings support the therapeutic potential of rapamycin as a neuroprotective agent. Graphical abstractKeywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (CB-2013-221615)
- Programa de Apoyo a la Investigacion Cientifica y Tecnologica (SA097-15)
This publication has 80 references indexed in Scilit:
- Tumor growth effects of rapamycin on human biliary tract cancer cellsEuropean Journal of Medical Research, 2012
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from LongevityScience, 2012
- Mammalian target of rapamycin signaling in diabetic cardiovascular diseaseCardiovascular Diabetology, 2012
- Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in ratsBritish Journal of Pharmacology, 2011
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisNew England Journal of Medicine, 2011
- Rapamycin Protects against Neuron Death inIn VitroandIn VivoModels of Parkinson's DiseaseThe Journal of Neuroscience, 2010
- mTOR regulation of autophagyFEBS Letters, 2010
- The Possible Cellular Mechanism for Extending Lifespan of Mice with RapamycinBiological Procedures Online, 2009
- Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signallingThe EMBO Journal, 2008
- Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in YeastJournal of Biological Chemistry, 1998